Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultragenyx Pharmaceutical Inc.

www.ultragenyx.com

Latest From Ultragenyx Pharmaceutical Inc.

Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics

New US FDA draft guidance says that the agency will no longer change the proper names of originator biologics to include a four-letter suffix, although the agency will continue to attach suffixes to future approvals.
Biosimilars Biologics

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Bayer Bosses Beg Risk-Averse Europe To Rethink

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Regenerative Medicine Innovation

Kyowa Kirin Presses On With Parkinson's Prospect In US As Successor Readied

Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.

United States Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ultragenyx Pharmaceutical LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Emil Kakkis, MD, PhD, Pres. & CEO
    Shalini Sharp, EVP, CFO
    Thomas Kassberg, EVP, CBO
    Camille L Bedrosian, MD, EVP, CMO
    Wladimir Hogenhuis, COO
  • Contact Info
  • Ultragenyx Pharmaceutical Inc.
    Phone: (415) 483-8800
    60 Leveroni Ct.
    Novato, CA 94949
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register